Anti lamin b

TMZ, Compound C, AICAR, Mdivi1, MG132 and WY14643, were purchased from MedChemExpress company. MTT and N‐Acetyl‐L‐cysteine (NAC) were purchased from Sigma‐Aldrich. MitoTracker™ Red FM (M22425), Hoechst 33342 (H1399) and anti‐Ubiquitin WB Antibody (13–1600) were purchased from Invitrogen (Thermo Fisher Scientific, Inc.) (1:1,000). Anti‐phospho‐Ubiquitin (Ser65) (ABS1513‐I) was purchased from Merck KGaA company (1:1000). Anti‐P53 (21891–1‐AP), anti‐PINK1 (23274–1‐AP), anti‐Parkin (14060–1‐AP), anti‐Drp1 (12957–1‐AP), anti‐Opa1 (27733–1‐AP), anti‐Mfn1 (13798–1‐AP), anti‐Mfn2 (12186–1‐AP), anti‐Caspase‐9 (10380–1‐AP), anti‐BAX (50599–2‐Ig), anti‐Caspase‐3 (19677–1‐AP), anti‐VDAC1 (10866–1‐AP), anti‐Lamin B (12987–1‐AP), anti‐Cytochrome c (10993–1‐AP), and anti‐β‐actin (60008–1‐Ig) were purchased from ProteinTech Group, Inc., (Chicago, IL, USA) (1:1,000). Anti‐γ‐H2A.X (ab81299) was purchased from Abcam (1:1000). Anti‐AMPKα (2532) and p‐AMPKα (50081) were purchased from Cell Signaling Technology, Inc. (Massachusetts, USA) (1:1000). Anti‐phospho‐DRP1(Ser616) (DF2972) was purchased from Affinity Biosciences (1:1000). Anti‐phospho‐DRP1(Ser637) (6319S) was purchased from Cell Signaling Technology, Inc. (1:1,000).

WB was performed as previously described^{34 (link)}, using monoclonal anti-LIMK2 (1:1000; Abcam, Cambridge, MA, USA) and polyclonal anti-LIMK2 (1:1000; Proteintech, Chicago, IL, USA), anti-E-cadherin, anti-Vimentin, anti-Met, anti-c-myc, anti-c-jun (1:1000; Cell Signaling Technology, Danvers, MA, USA), anti-LIMK1, anti-β-catenin, anti-lamin B (1:1000; Proteintech, Chicago, IL, USA). The loading control was a mouse anti-GAPDH monoclonal antibody (1:10000; Proteintech, Chicago, IL, USA).

EGFP‐TFEB WT (38,119), mRFP‐GFP‐LC3B (84,573), EGFP‐α‐synucleinA53T (40,823), and PHM‐α‐synucleinA53T (40,825) were supplied by Addgene. GFP‐Adenovirus (AdV) and A53T‐AdV were purchased from Obio Technology. Corp. Ltd. anti‐α‐synuclein (10842‐1‐AP), anti‐PARP1 (13371‐1‐AP), anti‐TFEB (13372‐1‐AP), anti‐m‐TOR (20657‐1‐AP), anti‐LAMP1 (21997‐1‐AP), and anti‐Lamin B (12987‐1‐AP) were purchased from Proteintech; anti‐p‐m‐TOR (#5536), anti‐SIRT1 (#8469), anti‐β‐ACTB (#4970), anti‐LC3B A/B (#4211), and anti‐PGC‐1α (#2178s) were purchased from CST; anti‐TH (Santa, sc‐25269); anti‐γ‐H2A.X (Abcam, ab243906); anti‐PAR (Trevigen,4335‐MC‐100); Veliparib (Selleck, s1004); Veliparib (TargetMol; T2591); SRT2104 (Selleck, s7792); EX527(Selleck, s1541); CQ (Selleck, s8808); rapamycin (MedChenExpress, HY‐10219); and KPT‐330 (Selleck, s725).
Primers:
ACTB: F‐CATTGCTGACAGGATGCAGAAGG‐, R‐TGCTGGAAGGTGGACAGTGAGG‐
LC3B: F‐GGACCTGCTGCTTCTCTAA‐, R‐ACTGCTGAGTGAAAGGGTGT‐
LAMP1: F‐AGCCCTGGAATTGCAGTTTG‐, R‐CACTGTCCACCTTGAAAGCC‐
α‐synucleinA53T‐tg: F‐TGTAGGCTCCAAAACCAAGG‐, R‐TGTCAGGATCCACAGGCATA‐
siPARP1: F‐GCAGCGAGUAGUAUUCCCAAdTdT‐, R‐UUGGGAAUACUCUCGCUGCdTdT‐;
siSIRT1: F‐ACGAUGACAGAACGUCACAdTdT‐, R‐UGUGAGUUCUGUCAUCGUdTdT‐